Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
50 hedge funds and large institutions have $24.3M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 7 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
7% less funds holding
Funds holding: 54 → 50 (-4)
35% less capital invested
Capital invested by funds: $37.3M → $24.3M (-$13.1M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $273K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.57M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$604K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$406K |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$394K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.51M |
| 2 |
Morgan Stanley
New York
|
-$861K |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$685K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$356K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$330K |
JNP Hedge Fund Activity: Q1 2016 in Review
50 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2016, worth a combined $24.3M — down 35% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of JNP and 4 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 21 added.
The largest buyer was Heartland Advisors, opening a new position worth an estimated $1.57M. The largest seller was EAM Investors, exiting entirely with an estimated $1.51M sold.
- 50 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2016, down from 54 in Q4 2015.
- Funds reported $24.3M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2016, down 35% quarter-over-quarter.
- 4 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2016 and 7 closed out, a net change of -3 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2016 was Heartland Advisors, an estimated $1.57M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2016 was EAM Investors, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2016.